8-K: INVO Bioscience Secures $850,000 Investment Through Warrant Agreement with Triton Funds LP

INVO Bioscience has entered into an agreement with Triton Funds LP for the sale of up to 1,000,000 shares of common stock and warrants, potentially raising $850,000.

Summary

• INVO Bioscience has entered into a purchase agreement with Triton Funds LP, where Triton will purchase up to 1,000,000 shares of INVO's common stock at $0.85 per share, potentially providing gross proceeds of up to $850,000.
• The agreement includes the issuance of warrants to Triton, allowing them to purchase up to 1,000,000 additional shares at an exercise price of $2.00 per share.
• The purchase agreement is valid until the earlier of the sale of all 1,000,000 shares or December 31, 2024.
• Triton's purchases are subject to certain limitations, including a beneficial ownership cap of 9.99% of the outstanding shares, unless shareholder approval is obtained.
• The warrants are immediately exercisable and expire five years from the issue date, with a cashless exercise option available if a registration statement is not effective.
• The company is required to file a prospectus supplement to its existing registration statement to cover the offering and sale of these shares.

Sentiment

Score: 6

Explanation: The document indicates a necessary capital raise, which is positive for the company's operations but may cause some dilution for existing shareholders. The terms are fairly standard for this type of financing, so the sentiment is neutral to slightly positive.

Positives

• The agreement provides INVO Bioscience with a potential influx of up to $850,000 in capital.
• The warrants provide a potential future source of capital if exercised.
• The agreement allows for flexibility in the timing of share sales, based on market conditions and the company's funding needs.
• Triton is obligated to purchase shares when directed by INVO, providing a reliable source of funding.

Negatives

• The share price of $0.85 is below the warrant exercise price of $2.00, which may indicate a lower valuation.
• The potential dilution of existing shares if the warrants are exercised.
• The agreement is subject to market conditions and the company's decisions, which may affect the actual amount of capital raised.
• The company is required to obtain shareholder approval for the issuance of shares exceeding the Exchange Cap, which may not be guaranteed.

Risks

• The actual amount of capital raised may be less than $850,000 depending on the company's decisions and market conditions.
• The exercise of warrants could lead to further dilution of existing shareholders' equity.
• The company's ability to meet the requirements of Nasdaq Listing Rule 5635(d) could impact the issuance of shares.
• The company's share price could be negatively impacted by the issuance of new shares.
• There is no guarantee that the company will obtain shareholder approval for the issuance of shares exceeding the Exchange Cap.

Future Outlook

The company intends to use the proceeds from the share sales for general corporate purposes. The company will file a prospectus supplement to allow for the sale of shares to Triton. The company may seek shareholder approval to issue shares exceeding the Exchange Cap.

Management Comments

• The company has not provided any specific management comments in this document.

Industry Context

This type of financing is common for small-cap biotech companies seeking to raise capital for operations and development. The use of warrants is a typical method to attract investors in such financings.

Comparison to Industry Standards

• The use of a purchase agreement with a fund like Triton is a common method for small-cap biotech companies to raise capital.
• The warrant structure with a cashless exercise option is also a standard practice in these types of financings.
• The beneficial ownership limitation is a common clause to prevent a single investor from gaining too much control.
• The pricing of the shares at $0.85 and warrants at $2.00 is typical for companies with a lower market capitalization and higher risk profile.
• Comparable companies in the biotech sector often use similar financing methods, including private placements with warrants, to fund their operations and research.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company will have additional capital to fund operations.
• The agreement provides a potential source of funding for the company's future growth.

Next Steps

• The company will file a prospectus supplement with the SEC.
• The company may seek shareholder approval for the issuance of shares exceeding the Exchange Cap.
• The company will issue shares to Triton Funds LP as per the purchase agreement.
• Triton Funds LP may exercise the warrants to purchase additional shares.

Key Dates

Keywords

common stock, warrant, capital raise, Triton Funds LP, share purchase, private placement, equity financing, beneficial ownership, exercise price, prospectus supplement